Identification

Name
Tolfenamic Acid
Accession Number
DB09216
Type
Small Molecule
Groups
Approved, Investigational
Description

Tolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory agent.[2] It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam.[10] In the US, it presents a Status class I by the FDA. By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[9]

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Clotam (GEA Farmaceutisk Fabrik)
Categories
UNII
3G943U18KM
CAS number
13710-19-5
Weight
Average: 261.704
Monoisotopic: 261.05565634
Chemical Formula
C14H12ClNO2
InChI Key
YEZNLOUZAIOMLT-UHFFFAOYSA-N
InChI
InChI=1S/C14H12ClNO2/c1-9-11(15)6-4-8-12(9)16-13-7-3-2-5-10(13)14(17)18/h2-8,16H,1H3,(H,17,18)
IUPAC Name
2-[(3-chloro-2-methylphenyl)amino]benzoic acid
SMILES
CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O

Pharmacology

Indication

In the information for tolfenamic acid, it is stated that this drug, being an NSAID, is effective in treating the pain associated with the acute attack of migraines in adults.[11]

Structured Indications
Not Available
Pharmacodynamics

Studies have shown that tolfenamic acid presents a non-dose dependent partial inhibition of irritant-induced temperature rise as well as a dose-dependent inhibition of skin edema. By studying its NSAID properties more closely, it was noted a dose-related inhibition of serum thromboxane which indicated the inhibition of COX-1. In the same line, there was noted a inhibition of prostaglandin E2 synthesis which marks a related COX-2 inhibition.[3] The maximal inhibition of thromboxane was greater than 80% as well as is proven to be a potent prostaglandin E inhibitor.[4]

Mechanism of action

Tolfenamic acid inhibits the biosynthesis of prostaglandins, and it also presents inhibitory actions on the prostaglandin receptors.[2] As commonly thought, the mechanism of action of tolfenamic acid is based on the major mechanism of NSAIDs which consists of the inhibition of COX-1 and COX-2 pathways to inhibit prostaglandin secretion and action and thus, to exert its anti-inflammatory and pain-blocking action. Nonetheless, some report currently indicates that tolfenamic acid inhibits leukotriene B4 chemotaxis of human polymorphonuclear leukocytes leading to an inhibition of even 25% of the chemotactic response. This activity is a not ligand specific additional anti-inflammatory mechanism of tolfenamic acid.[5]

TargetActionsOrganism
AProstaglandin G/H synthase 1
antagonist
Human
AProstaglandin G/H synthase 2
antagonist
Human
Absorption

Tolfenamic acid pharmacokinetic is marked by a short tmax of 0.94-2.04 h.[3] It also presented a linear pharmacokinetic profile with an AUC from 13-50 mcg/ml.h if administered in a dose of 2-8 mg/kg respectively.[4] The oral absorption is delayed and it gives a mean lag-time to absorption of 32 min. The peak plasma concentration of 11.1 mcg/ml.[6] The bioavailability of tolfenamic acid is around 75%.[8]

Volume of distribution

The volume of distribution is of 1.79-3.2 L/kg.[3] When tested intravenously, the reported steady-state volume of distribution was 0.33 L/kg.[6]

Protein binding

Tolfenamic acid presents high protein binding properties reaching 99.7% of the administered dose.[1] Studies have studied the changes in protein binding depending on the presence of certain disorders that modify the dialysis equilibrium. These studies verify that modifications in blood creatinine, urea and bilirubin can significantly alter the concentration of unbound tolfenamic acid. The main binding structure is predicted to be related to lipid membrane structures.[7]

Metabolism

The first pass metabolism accounts for 20% of the administered dose of tolfenamic acid.[8] Urine metabolite studies have demonstrated the identification of five metabolites from which three of them are monohydroxylated, one is monohydroxylated and hydroxylated and one last metabolite that presented and oxidized methyl group to form a carboxyl group.[8] Two of these hydroxylated metabolites are N-(2-hydroxymethyl-3-chlorophenyl)-anthranilic acid and N-(2-hydroxymethyl-3-chloro-4-hydroxyphenyl)-anthranilic acid.[12]

Route of elimination

Tolfenamic acid is cleared relatively fast and it undergoes by hepatic metabolism where the produced metabolites are renally cleared as glucuronic acid conjugates.[8] Most of the elimination occurs by extrarenal mechanisms in which the unchanged drug together with its glucuronide in urine accounts for only 8.8% of the administered dose.[1]

Half life

The estimated half-life of tolfenamic acid is 8.01-13.50 hours.[3] When tested intravenously, the reported half-life was 6.1h.[6]

Clearance

The estimated clearance rate of tolfenamic acid is 0.142-0.175 L.h/kg.[3] When tested intravenously, the reported clearance rate was 72.4 ml.h/kg.[6]

Toxicity

Tolfenamic acid has a relatively low acute toxicity with LD50 values in 200-1000 mg/kg. The metabolites of tolfenamic acid are reported to have an even less important toxicity. Some of the expected toxicity is related to the presence of gastrointestinal effects such as gut ulceration and renal papillitis.[12]

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Tolfenamic Acid.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with 19-norandrostenedione.Experimental, Illicit
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Tolfenamic Acid.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Tolfenamic Acid.Vet Approved
5-androstenedioneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with 5-androstenedione.Experimental, Illicit
AbciximabTolfenamic Acid may increase the anticoagulant activities of Abciximab.Approved
AcebutololTolfenamic Acid may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Tolfenamic Acid.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolTolfenamic Acid may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tolfenamic Acid.Approved, Vet Approved
AclarubicinTolfenamic Acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Tolfenamic Acid.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Aldosterone.Experimental, Investigational
AldoxorubicinTolfenamic Acid may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Alendronic acid.Approved
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Tolfenamic Acid.Approved, Investigational
AliskirenTolfenamic Acid may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Alminoprofen.Experimental
AlprenololTolfenamic Acid may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Amcinonide.Approved
AmikacinTolfenamic Acid may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideTolfenamic Acid may decrease the antihypertensive activities of Amiloride.Approved
AmobarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
Amphotericin BThe therapeutic efficacy of Amphotericin B can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
AmrubicinTolfenamic Acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodTolfenamic Acid may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Tolfenamic Acid.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with anecortave acetate.Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Anisodamine.Investigational
AnnamycinTolfenamic Acid may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tolfenamic Acid.Approved, Investigational
Antithrombin III humanTolfenamic Acid may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanTolfenamic Acid may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Apocynin.Investigational
ApramycinTolfenamic Acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Tolfenamic Acid.Approved, Investigational
ArbekacinTolfenamic Acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinTolfenamic Acid may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanTolfenamic Acid may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Tolfenamic Acid.Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Tolfenamic Acid.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Atamestane.Investigational
AtenololTolfenamic Acid may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tolfenamic Acid.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tolfenamic Acid.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tolfenamic Acid.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Tolfenamic Acid.Investigational
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Tolfenamic Acid.Experimental
BalsalazideTolfenamic Acid may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BarbexacloneThe metabolism of Tolfenamic Acid can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Barbital.Illicit
BecaplerminTolfenamic Acid may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololTolfenamic Acid may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinTolfenamic Acid may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tolfenamic Acid.Approved
BenorilateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tolfenamic Acid.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
BenzydamineThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tolfenamic Acid.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Betamethasone.Approved, Vet Approved
BetaxololTolfenamic Acid may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Tolfenamic Acid.Approved, Investigational
BevantololTolfenamic Acid may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Bevonium.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
BisoprololTolfenamic Acid may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinTolfenamic Acid may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololTolfenamic Acid may decrease the antihypertensive activities of Bopindolol.Approved
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Tolfenamic Acid.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tolfenamic Acid.Approved
BucillamineThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Bucillamine.Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Tolfenamic Acid.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Bufexamac.Approved, Experimental
BufuralolTolfenamic Acid may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Tolfenamic Acid.Approved
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Tolfenamic Acid.Investigational
BupranololTolfenamic Acid may decrease the antihypertensive activities of Bupranolol.Approved
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Tolfenamic Acid.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Tolfenamic Acid.Approved
Calcium AcetateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Phosphate.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Tolfenamic Acid.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Tolfenamic Acid.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Tolfenamic Acid.Withdrawn
CandoxatrilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Candoxatril.Experimental
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Tolfenamic Acid.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tolfenamic Acid.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Tolfenamic Acid.Approved, Vet Approved, Withdrawn
CarteololTolfenamic Acid may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Tolfenamic Acid.Approved, Investigational
CaseinThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Tolfenamic Acid.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tolfenamic Acid.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Celecoxib.Approved, Investigational
CeliprololTolfenamic Acid may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinTolfenamic Acid may increase the anticoagulant activities of Certoparin.Approved, Investigational
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Tolfenamic Acid.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tolfenamic Acid.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tolfenamic Acid.Approved, Vet Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Tolfenamic Acid.Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tolfenamic Acid.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Tolfenamic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tolfenamic Acid.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ciclesonide.Approved, Investigational
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Cilazapril.Approved
CimetidineThe serum concentration of Tolfenamic Acid can be increased when it is combined with Cimetidine.Approved, Investigational
CinoxacinTolfenamic Acid may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidTolfenamic Acid may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clonixin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Tolfenamic Acid.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Tolfenamic Acid.Vet Approved
CloranololTolfenamic Acid may decrease the antihypertensive activities of Cloranolol.Experimental
ClotrimazoleThe therapeutic efficacy of Clotrimazole can be increased when used in combination with Tolfenamic Acid.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Tolfenamic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Tolfenamic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Tolfenamic Acid.Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tolfenamic Acid.Experimental
CyclosporineTolfenamic Acid may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateTolfenamic Acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinTolfenamic Acid may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTolfenamic Acid may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanTolfenamic Acid may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinTolfenamic Acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Delapril.Experimental
DesirudinTolfenamic Acid may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Tolfenamic Acid.Approved, Investigational
DextranTolfenamic Acid may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Dextran 40Tolfenamic Acid may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Tolfenamic Acid may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Tolfenamic Acid may increase the anticoagulant activities of Dextran 75.Approved
DibekacinTolfenamic Acid may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Dibotermin alfa.Approved, Investigational
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Tolfenamic Acid.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tolfenamic Acid.Approved, Vet Approved
DicoumarolTolfenamic Acid may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tolfenamic Acid.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Tolfenamic Acid.Approved
DihydrostreptomycinTolfenamic Acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Tolfenamic Acid.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Tolfenamic Acid.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Tolfenamic Acid.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Tolfenamic Acid.Approved
DoxorubicinTolfenamic Acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneTolfenamic Acid may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Tolfenamic Acid.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with E-6201.Investigational
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Tolfenamic Acid.Approved
Edetic AcidTolfenamic Acid may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTolfenamic Acid may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Tolfenamic Acid.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Enalaprilat.Approved
EnoxacinTolfenamic Acid may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinTolfenamic Acid may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Tolfenamic Acid.Experimental
EpanololTolfenamic Acid may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Tolfenamic Acid.Approved
EpirubicinTolfenamic Acid may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Tolfenamic Acid.Experimental
EplerenoneTolfenamic Acid may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tolfenamic Acid.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tolfenamic Acid.Approved
EquileninThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Equilin.Approved
EsmololTolfenamic Acid may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Tolfenamic Acid.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ethenzamide.Experimental
Ethyl biscoumacetateTolfenamic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Tolfenamic Acid.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Evening primrose oil.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Tolfenamic Acid.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Tolfenamic Acid.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Tolfenamic Acid.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tolfenamic Acid.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Tolfenamic Acid.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fentiazac.Experimental
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Tolfenamic Acid.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Feprazone.Experimental
Ferulic acidTolfenamic Acid may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tolfenamic Acid.Approved, Investigational
FleroxacinTolfenamic Acid may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Tolfenamic Acid.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluasterone.Investigational
FluconazoleThe therapeutic efficacy of Fluconazole can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fludrocortisone.Approved, Investigational
FluindioneTolfenamic Acid may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineTolfenamic Acid may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Tolfenamic Acid.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tolfenamic Acid.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluticasone propionate.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Tolfenamic Acid.Experimental
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tolfenamic Acid.Approved, Nutraceutical, Vet Approved
FondaparinuxTolfenamic Acid may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumTolfenamic Acid may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Tolfenamic Acid.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fosinopril.Approved
FramycetinTolfenamic Acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Tolfenamic Acid.Approved, Vet Approved
GabexateTolfenamic Acid may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinTolfenamic Acid may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinTolfenamic Acid may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Tolfenamic Acid.Approved, Withdrawn
GemifloxacinTolfenamic Acid may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinTolfenamic Acid may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinTolfenamic Acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ATolfenamic Acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Tolfenamic Acid.Experimental
GPX-150Tolfenamic Acid may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinTolfenamic Acid may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Tolfenamic Acid.Approved, Investigational, Vet Approved
GuacetisalThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Guacetisal.Experimental
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Tolfenamic Acid.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Haloperidol.Approved
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Tolfenamic Acid.Approved, Withdrawn
HE3286The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with HE3286.Investigational
HeparinTolfenamic Acid may increase the anticoagulant activities of Heparin.Approved, Investigational
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
HexobarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Hexobarbital.Approved
HigenamineThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Higenamine.Investigational
HydralazineTolfenamic Acid may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tolfenamic Acid.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
Hygromycin BTolfenamic Acid may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tolfenamic Acid.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Tolfenamic Acid.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Tolfenamic Acid.Approved, Investigational
IdarubicinTolfenamic Acid may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxTolfenamic Acid may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tolfenamic Acid.Approved
IndenololTolfenamic Acid may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tolfenamic Acid.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Tolfenamic Acid.Withdrawn
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Tolfenamic Acid.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tolfenamic Acid.Approved, Investigational
IsepamicinTolfenamic Acid may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Tolfenamic Acid.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Tolfenamic Acid.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Istaroxime.Investigational
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
KanamycinTolfenamic Acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Tolfenamic Acid.Experimental
KetoconazoleThe therapeutic efficacy of Ketoconazole can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tolfenamic Acid.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tolfenamic Acid.Approved
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Tolfenamic Acid.Approved
LandiololTolfenamic Acid may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Tolfenamic Acid.Approved, Investigational
LepirudinTolfenamic Acid may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanTolfenamic Acid may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololTolfenamic Acid may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinTolfenamic Acid may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Tolfenamic Acid.Approved
LonazolacThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tolfenamic Acid.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Tolfenamic Acid.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Tolfenamic Acid.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Tolfenamic Acid.Vet Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Tolfenamic Acid is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Tolfenamic Acid is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Tolfenamic Acid is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Tolfenamic Acid is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tolfenamic Acid.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tolfenamic Acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tolfenamic Acid.Approved
MelagatranTolfenamic Acid may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tolfenamic Acid.Approved, Vet Approved
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Tolfenamic Acid.Experimental
MepindololTolfenamic Acid may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineTolfenamic Acid may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Tolfenamic Acid.Approved, Investigational, Withdrawn
MethohexitalThe metabolism of Tolfenamic Acid can be increased when combined with Methohexital.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Tolfenamic Acid.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tolfenamic Acid.Approved
MethylphenobarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Methylprednisolone.Approved, Vet Approved
MetipranololTolfenamic Acid may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tolfenamic Acid.Approved
MetoprololTolfenamic Acid may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideTolfenamic Acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Tolfenamic Acid.Experimental
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Tolfenamic Acid.Approved, Investigational, Vet Approved
MicronomicinTolfenamic Acid may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Tolfenamic Acid.Approved, Experimental
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tolfenamic Acid.Approved
MizoribineThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Mometasone.Approved, Vet Approved
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Tolfenamic Acid.Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tolfenamic Acid.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tolfenamic Acid.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tolfenamic Acid.Approved
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Tolfenamic Acid.Experimental
NabumetoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Nabumetone.Approved
NadololTolfenamic Acid may decrease the antihypertensive activities of Nadolol.Approved
NadroparinTolfenamic Acid may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatTolfenamic Acid may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NafcillinThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Tolfenamic Acid.Approved
Nalidixic AcidTolfenamic Acid may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Tolfenamic Acid.Approved, Vet Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Tolfenamic Acid.Approved
NCX 1022The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with NCX 1022.Investigational
NeamineTolfenamic Acid may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololTolfenamic Acid may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinTolfenamic Acid may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinTolfenamic Acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tolfenamic Acid.Approved, Investigational
NetilmicinTolfenamic Acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tolfenamic Acid.Approved
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Tolfenamic Acid.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Tolfenamic Acid.Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tolfenamic Acid.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Nitroaspirin.Investigational
NitroprussideTolfenamic Acid may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Tolfenamic Acid.Approved
NorfloxacinTolfenamic Acid may increase the neuroexcitatory activities of Norfloxacin.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Tolfenamic Acid.Approved, Vet Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tolfenamic Acid.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tolfenamic Acid.Approved
OlsalazineTolfenamic Acid may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Tolfenamic Acid is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Omapatrilat.Investigational
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Tolfenamic Acid.Experimental
OrgoteinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Orgotein.Vet Approved
OtamixabanTolfenamic Acid may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tolfenamic Acid.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Tolfenamic Acid.Approved
Oxolinic acidTolfenamic Acid may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololTolfenamic Acid may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tolfenamic Acid.Approved, Withdrawn
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Tolfenamic Acid.Investigational
PamidronateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Parecoxib.Approved
ParomomycinTolfenamic Acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Parthenolide.Approved, Investigational
PazufloxacinTolfenamic Acid may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinTolfenamic Acid may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololTolfenamic Acid may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateTolfenamic Acid may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
PentobarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
Pentosan PolysulfateTolfenamic Acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Perindopril.Approved
PhenindioneTolfenamic Acid may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Phenobarbital.Approved, Investigational
PhenprocoumonTolfenamic Acid may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tolfenamic Acid.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tolfenamic Acid.Approved, Investigational
PindololTolfenamic Acid may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidTolfenamic Acid may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinTolfenamic Acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Tolfenamic Acid.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tolfenamic Acid.Approved, Investigational
Piromidic acidTolfenamic Acid may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tolfenamic Acid.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorTolfenamic Acid may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinTolfenamic Acid may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinTolfenamic Acid may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tolfenamic Acid.Approved
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Tolfenamic Acid.Approved, Investigational, Vet Approved
PractololTolfenamic Acid may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Tolfenamic Acid.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Prasterone sulfate.Investigational
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Tolfenamic Acid.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pregnenolone.Approved, Experimental, Investigational
PrimidoneThe metabolism of Tolfenamic Acid can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Tolfenamic Acid can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Propacetamol.Approved, Investigational
PropranololTolfenamic Acid may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Tolfenamic Acid.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Tolfenamic Acid.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Tolfenamic Acid.Vet Approved
Protein CTolfenamic Acid may increase the anticoagulant activities of Protein C.Approved
Protein S humanTolfenamic Acid may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTolfenamic Acid may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinTolfenamic Acid may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Tolfenamic Acid.Investigational
PuromycinTolfenamic Acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Tolfenamic Acid.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tolfenamic Acid.Approved
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Tolfenamic Acid.Experimental
RamiprilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tolfenamic Acid.Approved, Experimental, Investigational
ReviparinTolfenamic Acid may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinTolfenamic Acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Tolfenamic Acid.Approved, Investigational
RifampicinThe risk or severity of hypotension can be increased when Rifampicin is combined with Tolfenamic Acid.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Tolfenamic Acid.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Tolfenamic Acid.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Risedronate.Approved, Investigational
RivaroxabanTolfenamic Acid may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinTolfenamic Acid may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinTolfenamic Acid may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinTolfenamic Acid may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Tolfenamic Acid.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tolfenamic Acid.Approved
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Tolfenamic Acid.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tolfenamic Acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Tolfenamic Acid.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tolfenamic Acid.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Tolfenamic Acid.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Tolfenamic Acid.Approved, Investigational
SecobarbitalThe metabolism of Tolfenamic Acid can be increased when combined with Secobarbital.Approved, Vet Approved
SemapimodThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tolfenamic Acid.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Serrapeptase.Investigational
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Tolfenamic Acid.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Tolfenamic Acid.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
SisomicinTolfenamic Acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinTolfenamic Acid may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Tolfenamic Acid.Approved
SotalolTolfenamic Acid may decrease the antihypertensive activities of Sotalol.Approved
SP1049CTolfenamic Acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinTolfenamic Acid may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinTolfenamic Acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Spirapril.Approved
SpironolactoneTolfenamic Acid may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Tolfenamic Acid.Investigational
StreptomycinTolfenamic Acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinTolfenamic Acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Tolfenamic Acid.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tolfenamic Acid.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Tolfenamic Acid.Approved, Investigational
SulodexideTolfenamic Acid may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Tolfenamic Acid.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Tolfenamic Acid.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Suxibuzone.Experimental
TacrolimusTolfenamic Acid may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Tolfenamic Acid.Approved
TalinololTolfenamic Acid may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Tolfenamic Acid.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Tolfenamic Acid.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Tolfenamic Acid.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tolfenamic Acid.Approved
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tolfenamic Acid.Approved, Investigational
TemafloxacinTolfenamic Acid may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tolfenamic Acid.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Tolfenamic Acid.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Tolfenamic Acid.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Tolfenamic Acid.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Tolfenamic Acid.Approved
TertatololTolfenamic Acid may decrease the antihypertensive activities of Tertatolol.Experimental
ThiamylalThe metabolism of Tolfenamic Acid can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Tolfenamic Acid can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Tolfenamic Acid.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tolfenamic Acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololTolfenamic Acid may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Tinoridine.Investigational
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Tolfenamic Acid.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Tixocortol.Approved, Withdrawn
TobramycinTolfenamic Acid may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Tolfenamic Acid.Experimental
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tolfenamic Acid.Approved
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Tolfenamic Acid.Approved, Investigational, Vet Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Tolfenamic Acid.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Tolfenamic Acid.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tolfenamic Acid.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tolfenamic Acid.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Triamcinolone.Approved, Vet Approved
TriamtereneTolfenamic Acid may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tolfenamic Acid.Approved, Vet Approved
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Tolfenamic Acid.Experimental
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
TriptolideThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Triptolide.Investigational
TrovafloxacinTolfenamic Acid may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinTolfenamic Acid may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Tolfenamic Acid.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValrubicinTolfenamic Acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Tolfenamic Acid.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Tolfenamic Acid.Approved
VoriconazoleThe therapeutic efficacy of Voriconazole can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
WarfarinTolfenamic Acid may increase the anticoagulant activities of Warfarin.Approved
XimelagatranTolfenamic Acid may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tolfenamic Acid.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Tolfenamic Acid.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tolfenamic Acid.Withdrawn
Zoptarelin doxorubicinTolfenamic Acid may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinTolfenamic Acid may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
  1. Pentikainen PJ, Neuvonen PJ, Backman C: Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent. Eur J Clin Pharmacol. 1981;19(5):359-65. [PubMed:7238564]
  2. Tokola RA, Neuvonen PJ: Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol. 1984 Jan;17(1):67-75. [PubMed:6691890]
  3. Lees P, McKellar QA, Foot R, Gettinby G: Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation. Vet J. 1998 May;155(3):275-88. [PubMed:9638074]
  4. McKellar QA, Lees P, Gettinby G: Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. Eur J Pharmacol. 1994 Mar 3;253(3):191-200. [PubMed:8200415]
  5. Kankaanranta H, Moilanen E, Vapaatalo H: Tolfenamic acid inhibits leukotriene B4-induced chemotaxis of polymorphonuclear leukocytes in vitro. Inflammation. 1991 Apr;15(2):137-43. [PubMed:1649132]
  6. Jaussaud P, Guieu D, Bellon C, Barbier B, Lhopital MC, Sechet R, Courtot D, Toutain PL: Pharmacokinetics of tolfenamic acid in the horse. Equine Vet J Suppl. 1992 Feb;(11):69-72. [PubMed:9109966]
  7. Laznicek M, Senius KE: Protein binding of tolfenamic acid in the plasma from patients with renal and hepatic disease. Eur J Clin Pharmacol. 1986;30(5):591-6. [PubMed:3758148]
  8. Pedersen SB: Biopharmaceutical aspects of tolfenamic acid. Pharmacol Toxicol. 1994;75 Suppl 2:22-32. [PubMed:7816776]
  9. EMA [Link]
  10. European Journal of Chemistry [Link]
  11. Clotam leaflet [Link]
  12. EMA [Link]
External Links
Human Metabolome Database
HMDB0042043
KEGG Drug
D01183
PubChem Compound
610479
PubChem Substance
310265123
ChemSpider
530683
BindingDB
35905
ChEBI
32243
ChEMBL
CHEMBL121626
PharmGKB
PA166049189
HET
TLF
Wikipedia
Tolfenamic_acid
ATC Codes
M01AG02 — Tolfenamic acid
PDB Entries
4g77 / 5ikt / 6ap6
MSDS
Download (25.5 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)207ºC Deriv of anthranilic acid, related structurally to mefenamic and flufenamic acids. (1966)
water solubility1 mg/ml'MSDS'
logP5.17US-EPA
pKa5.11Mefenamic acid: analytical profile. (2005)
Predicted Properties
PropertyValueSource
Water Solubility0.0158 mg/mLALOGPS
logP4.64ALOGPS
logP5.49ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)3.88ChemAxon
pKa (Strongest Basic)-2.1ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area49.33 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity71.65 m3·mol-1ChemAxon
Polarizability26.46 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-1290000000-90928e5629bf0b4869e8
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a59-2790000000-175a0f838779d665e3db

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Aminobenzoic acids
Alternative Parents
Benzoic acids / Aminotoluenes / Aniline and substituted anilines / Benzoyl derivatives / Chlorobenzenes / Aryl chlorides / Vinylogous amides / Amino acids / Secondary amines / Monocarboxylic acids and derivatives
show 6 more
Substituents
Aminobenzoic acid / Benzoic acid / Benzoyl / Aniline or substituted anilines / Aminotoluene / Chlorobenzene / Halobenzene / Toluene / Aryl chloride / Aryl halide
show 18 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
organochlorine compound, secondary amino compound, aminobenzoic acid (CHEBI:32243)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Lees P, McKellar QA, Foot R, Gettinby G: Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation. Vet J. 1998 May;155(3):275-88. [PubMed:9638074]
  2. McKellar QA, Lees P, Gettinby G: Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. Eur J Pharmacol. 1994 Mar 3;253(3):191-200. [PubMed:8200415]
  3. Tokola RA, Neuvonen PJ: Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol. 1984 Jan;17(1):67-75. [PubMed:6691890]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Lees P, McKellar QA, Foot R, Gettinby G: Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation. Vet J. 1998 May;155(3):275-88. [PubMed:9638074]
  2. McKellar QA, Lees P, Gettinby G: Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. Eur J Pharmacol. 1994 Mar 3;253(3):191-200. [PubMed:8200415]
  3. Tokola RA, Neuvonen PJ: Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol. 1984 Jan;17(1):67-75. [PubMed:6691890]

Drug created on October 21, 2015 10:21 / Updated on March 02, 2018 03:47